Stock Market Reviews

SION (Sionna Therapeutics, Inc.) News

Get the latest news, insights, and market updates on SION (Sionna Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High?
  The mean of analysts' price targets for Sionna Therapeutics, Inc. (SION) points to a 66.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Sep 9, 2025 - $SION
• Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
  WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer (CBO). “We are delighted to welcome Caroline to our ex
  Sep 8, 2025 - $SION
• Sionna Therapeutics to Participate in Upcoming September Investor Conferences
  WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: Cantor Global Healthcare Conference
  Aug 27, 2025 - $SION
• Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
  Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protei
  Aug 25, 2025 - $SION
• Sionna Therapeutics Reports Second Quarter 2025 Financial Results
  Announced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded pharmacokinetic targets Initiation of Phase 2a proof-of-concept trial of SION-719 as an add-on to standard of care in cystic fibrosis patients is on track for the second half of 2025 with topline data expected in mid-2026 Advancement of Phase 1 healthy volunteer trial of SION-451 in two proprietary dual combinations is on track for the second hal
  Aug 11, 2025 - $SION
• Here's Why We're Not Too Worried About Sionna Therapeutics' (NASDAQ:SION) Cash Burn Situation
  Just because a business does not make any money, does not mean that the stock will go down. For example, although...
  Jul 28, 2025 - $SION
• Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
  Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the presentation of preclinical
  Jun 6, 2025 - $SION
• Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
  Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company’s first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna’s preclinical cystic fibrosis (CF) human
  Jun 4, 2025 - $SION
• Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis
  SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial Next trials to initiate in the second half of 2025 with topline data expected in mid-2026 Sionna to hold a
  Jun 4, 2025 - $SION
• Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
  WALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Healthcare Conference in Miami, Florida on We
  Jun 3, 2025 - $SION